IMUNON INC. - COMMON STOCK

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

06 May 2025 08:05:00 By Nasdaq GlobeNewswire

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

05 May 2025 08:00:00 By Nasdaq GlobeNewswire

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

21 Apr 2025 08:05:00 By Nasdaq GlobeNewswire

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

24 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

27 Feb 2025 08:05:00 By Nasdaq GlobeNewswire

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

26 Feb 2025 08:05:00 By Nasdaq GlobeNewswire

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

20 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

19 Feb 2025 08:05:00 By Nasdaq GlobeNewswire

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer 

10 Feb 2025 08:05:00 By Nasdaq GlobeNewswire

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

19 Dec 2024 08:05:00 By Nasdaq GlobeNewswire

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

10 Dec 2024 08:05:00 By Nasdaq GlobeNewswire

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

25 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

07 Nov 2024 10:00:00 By Nasdaq GlobeNewswire

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

07 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

31 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

30 Oct 2024 09:05:00 By Nasdaq GlobeNewswire

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

07 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09 Sep 2024 16:06:00 By Nasdaq GlobeNewswire

IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON to Host R&D Day on September 18th

28 Aug 2024 08:30:00 By Nasdaq GlobeNewswire